NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Protai

Protai

Private
GivatayimHealthcare & Life Scienceshttps://protai.bio/

Last Round

Seed

Mar 15, 2023

Total Funding Raised

$20M

Company Overview

Protai is a biotechnology company that has developed an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

proteomicsdrug discoveryAI drug discoverysmall moleculetarget identificationin silico drug discoveryclinical proteomicstherapeutic targetprecision medicinebiotech AIproteome mappingdrug developmentundruggable targetsAI-driven discoverycomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Protai Comparables

Compare Protai with similar companies based on industry and business-model similarity.

Protai comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Foreseen Biotechnology
86%
ProFound Therapeutics
86%
Promise Bio
84%

Protai Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 15, 2023
SeedJan 5, 2022

Key People

Founding team and executive leadership

Kirill Pevzner

CTO Co-founder

Founding Team

Eran Seger

CEO Co-founder

Founding Team

Protai Investors

Notable investors and investment history

Protai investors
InvestorRounds
Maj Invest Equity A/SSeed
Grove VenturesSeed
Pitango Venture CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 23, 2025

    Attending ACR Convergence 2025 to expand into Immunology & Inflammation.

Protai Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Protai Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Protai's valuation, stock price, and market status.

Firmographic Details

HeadquartersGivatayim
Employee Range29
Year Founded2021
Last FundingMar 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.